Purpose
We aimed to develop a preoperative risk scoring system to predict early recurrence (ER) of intrahepatic cholangiocarcinoma (ICCA) after resection, utilizing clinical and computed tomography (CT) features.
Materials and Methods
This multicenter study included 365 patients who underwent curative-intent surgical resection for ICCA at six institutions between 2009 and 2016. Of these, 264 patients from one institution constituted the development cohort, while 101 patients from the other institutions constituted the external validation cohort. Logistic regression models were constructed to predict ER based on preoperative variables and were subsequently translated into a risk-scoring system. The discrimination performance of the risk-scoring system was validated using external data and compared to the American Joint Committee on Cancer (AJCC) TNM staging system.
Results
Among the 365 patients (mean age, 62±10 years), 153 had ER. A preoperative risk scoring system that incorporated both clinical and CT features demonstrated superior discriminatory performance compared to the postoperative AJCC TNM staging system in both the development (area under the curve [AUC], 0.78 vs. 0.68; p=0.002) and validation cohorts (AUC, 0.69 vs. 0.66; p=0.641). The preoperative risk scoring system effectively stratified patients based on their risk for ER: the 1-year recurrence-free survival rates for the low, intermediate, and high-risk groups were 85.5%, 56.6%, and 15.6%, respectively (p<0.001) in the development cohort, and 87.5%, 58.5%, and 25.0%, respectively (p<0.001) in the validation cohort.
Conclusion
A preoperative risk scoring system that incorporates clinical and CT imaging features was valuable in identifying high-risk patients with ICCA for ER following resection.
Purpose Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.
Materials and Methods Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.
Results One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).
Conclusion “Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
Purpose
The purpose of this study was to investigate the impact of contrast enhanced pancreatic magnetic resonance imaging (MRI) in resectability and prognosis evaluation after staging computed tomography (CT) in patients with pancreatic ductal adenocarcinoma (PDA).
Materials and Methods
From January 2005 to December 2012, 298 patients were diagnosed to have potentially resectable stage PDA on CT. Patients were divided into CT+MR (patients underwent both CT and MRI; n=216) and CT only groups (n=82). Changes in resectability staging in the CT+MR group were evaluated. The overall survival was compared between the two groups. The recurrence-free survival and median time to liver metastasis after curative surgery were compared between the two groups.
Results
Staging was changed from resectable on CT to unresectable state on MRI in 14.4% of (31 of 216 patients) patients of the CT+MR group. The overall survival and recurrence-free survival rates were not significantly different between the two groups (p=0.162 and p=0.721, respectively). The median time to liver metastases after curative surgery in the CT+MR group (9.9 months) was significantly longer than that in the CT group (4.2 months) (p=0.011).
Conclusion
Additional MRI resulted in changes of resectability and treatment modifications in a significant proportion of patients who have potentially resectable state at CT and in prolonged time to liver metastases in patients after curative surgery. Additional MRI to standard staging CT can be recommended for surgical candidates of PDA.
Citations
Citations to this article as recorded by
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments Doaa Bugazia, Ebtesam Al-Najjar, Abdullah Esmail, Saifudeen Abdelrahim, Karen Abboud, Adham Abdelrahim, Godsfavour Umoru, Hashem A. Rayyan, Ala Abudayyeh, Ala-Eddin Al Moustafa, Maen Abdelrahim Frontiers in Oncology.2024;[Epub] CrossRef
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1 Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl Zeitschrift für Gastroenterologie.2024; 62(10): e874. CrossRef
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1 Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl Zeitschrift für Gastroenterologie.2024; 62(10): 1724. CrossRef
Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis Felix G. Gassert, Sebastian Ziegelmayer, Johanna Luitjens, Florian T. Gassert, Fabian Tollens, Johann Rink, Marcus R. Makowski, Johannes Rübenthaler, Matthias F. Froelich European Radiology.2022; 32(4): 2448. CrossRef
Diagnostik beim Pankreaskarzinom – Update in der neuen Leitlinie L. Grenacher, M. Juchems, A. G. Schreyer, J. Wessling, K. I. Ringe, W. Uhl, J. Mayerle, T. Seufferlein Der Chirurg.2022; 93(5): 429. CrossRef
Pancreatic adenocarcinoma: imaging techniques for diagnosis and management Jawaad Farrukh, Ravivarma Balasubramaniam, Anitha James, Sharan S Wadhwani, Raneem Albazaz British Journal of Hospital Medicine.2022; 83(5): 1. CrossRef
S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl Zeitschrift für Gastroenterologie.2022; 60(06): 991. CrossRef
S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl Zeitschrift für Gastroenterologie.2022; 60(11): e812. CrossRef
The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma Hyungjin Rhee, Mi-Suk Park Korean Journal of Radiology.2021; 22(1): 23. CrossRef
A Comparative Study of Survivor Outcomes between Preoperative Evaluation Using CT Alone and Combined CT and MRI in Patients with Pancreatic Ductal Adenocarcinoma Ji Eun Lee, Seong Hyun Kim, Soon Jin Lee, Seo-Youn Choi, Sunyoung Lee, Bo Ra Lee Journal of the Korean Society of Radiology.2021; 82(3): 638. CrossRef
СT and MRI in the assessment of resectable and borderline resectable pancreatic tumors A. V. Kudryavtseva, S. S. Bagnenko, I. I. Dzidzawa, I. S. Zheleznyak, G. E. Trufanov, V. V. Ryazanov, V. A. Krasovskaya, A. B. Kotiv, A. D. Kazakov Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2021; 26(1): 34. CrossRef
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Graça Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferollà, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzillet Cancer Treatment Reviews.2021; 99: 102208. CrossRef
ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Masayuki Sho, Masaji Tani, Ippei Matsumoto, Suguru Yamada, Ryosuke Amano, Hirochika Toyama, Yo-ichi Yamashita, Takeshi Gocho, Kazuto Shibuya, Minako Nagai, Hiromitsu Maehira, Keiko Kamei, Go Ohira, Yoshihiro Shi Trials.2021;[Epub] CrossRef
Management of Primary Squamous Cell Carcinoma of the Pancreas: A Case Report Danling Guo, Chao Chen, Sangying Lv, Guanzuan Wu, Wei Shi, Huaifeng Li, Hongjie Hu Frontiers in Surgery.2021;[Epub] CrossRef
Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC Min Woo Kim, Hani Koh, Jee Ye Kim, Suji Lee, Hyojung Lee, Young Kim, Ho Kyoung Hwang, Seung Il Kim International Journal of Molecular Sciences.2021; 22(24): 13621. CrossRef
Imaging and Management of Pancreatic Cancer Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg Seminars in Ultrasound, CT and MRI.2020; 41(2): 139. CrossRef
DUPLICATE: Imaging and Management of Pancreatic Cancer Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg Seminars in Ultrasound, CT and MRI.2019;[Epub] CrossRef
Purpose
This study was conducted to compare the diagnostic performance and early recurrence rate between gadoxetic acid–enhanced magnetic resonance imaging (Gd-EOB-MRI) and magnetic resonance imaging (MRI) with extracellular contrast agent (ECA-MRI) for evaluating hepatic lesions in colorectal cancer.
Materials and Methods
Between 2005 and 2010, 418 colorectal cancer patients with both preoperative computed tomography (CT) and liver MRI were retrospectively reviewed. Image analysis was based on initial radiologic reports, and diagnostic performance was assessed based on the area under the receiver operating characteristic curve (AUROC). The early intrahepatic recurrence rate within 6 months was then evaluated.
Results
Overall, 291 and 127 patients underwent Gd-EOB-MRI and ECA-MRI, respectively. The AUROCs were not significantly different between Gd-EOB-MRI (0.990; 95% CI, 0.980 to 0.999) and ECA-MRI (0.985; 95% CI, 0.968 to 1.000; p=0.836). When compared with CT alone, ECA-MRI detected additional 21 lesions in 14 patients (14/127, 11.0%), whereas Gd-EOB-MRI detected 56 lesions in 33 patients (33/291, 11.3%) without a significant difference between two MRI groups (p=0.331). The early recurrence rate in the ECA-MRI (28.6%) was significantly higher than that in the Gd-EOB-MRI (11.6%) for patients who underwent hepatic resection (p=0.031).
Conclusion
Gd-EOB-MRI is potentially better than ECA-MRI for decreasing the early intrahepatic recurrence rate, although the two MRI modalities showed comparable diagnostic performance in colorectal cancer patients.
Citations
Citations to this article as recorded by
Clinical performance of a simulated abbreviated liver magnetic resonance imaging in combination with contrast-enhanced computed tomography for the baseline evaluation of the liver in patients with colorectal cancer F. Castagnoli, S.J. Withey, M. Konidari, I. Chau, A. Riddell, J. Shur, C. Messiou, D.M. Koh Clinical Radiology.2025; 80: 106743. CrossRef
Collaborative multi-feature extraction and scale-aware semantic information mining for medical image segmentation Ruijun Zhang, Zixuan He, Jian Zhu, Xiaochen Yuan, Guoheng Huang, Chi-Man Pun, Jianhong Peng, Junzhong Lin, Jian Zhou Physics in Medicine & Biology.2022; 67(20): 205008. CrossRef
Diagnostic Performance of Deep Learning-Based Lesion Detection Algorithm in CT for Detecting Hepatic Metastasis from Colorectal Cancer Kiwook Kim, Sungwon Kim, Kyunghwa Han, Heejin Bae, Jaeseung Shin, Joon Seok Lim Korean Journal of Radiology.2021; 22(6): 912. CrossRef
Application of intraoperative ultrasound in liver surgery Ya-Wei Xu, Hong Fu Hepatobiliary & Pancreatic Diseases International.2021; 20(5): 501. CrossRef
Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang Cancer Research and Treatment.2019; 51(1): 24. CrossRef
Abbreviated Gadoxetic Acid–enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation Jeong Woo Kim, Chang Hee Lee, Yang Shin Park, Jongmee Lee, Kyeong Ah Kim Radiology: Imaging Cancer.2019; 1(1): e190006. CrossRef
Intraoperative Ultrasound Staging for Colorectal Liver Metastases in the Era of Liver-Specific Magnetic Resonance Imaging: Is It Still Worthwhile? Serena Langella, Francesco Ardito, Nadia Russolillo, Elena Panettieri, Serena Perotti, Caterina Mele, Felice Giuliante, Alessandro Ferrero Journal of Oncology.2019; 2019: 1. CrossRef
Capabilities of 18F-FDG PET/CT in the differential diagnosis of colorectal liver metastases M. S. Tlostanova, A. L. Dolbov, A. A. Stanzhevskii Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2019; 24(4): 18. CrossRef
Imagerie par résonance magnétique dans le bilan local préopératoire des cancers du rectum M. Djelouah, C. Durot, S. Deguelte-Lardière, J. Cohen, A. Devie, L. Protin-Catteau, C. Hoeffel EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2019; 37(2): 1. CrossRef
Purpose The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiogenic factors (CAFs) as pharmacodynamic and prognostic biomarkers of bevacizumab monotherapy in colorectal cancer with liver metastasis (CRCLM). Materials and Methods From July 2011 to March 2012, 28 patients with histologically confirmed CRCLM received bevacizumab monotherapy followed by combined FOLFOX therapy. The mean age of the patients was 57 years (range, 30 to 77 years). DCE-MRI (Ktransand IAUC60) was performed at baseline, first follow-up (3 days after bevacizumab monotherapy), and second follow-up (3 days after combined therapy). CAF levels (vascular endothelial growth factor [VEGF], placental growth factor [PlGF], and interleukin-8) were assessed on the same days. Progression-free survival (PFS) time distributions were summarized using the Kaplan-Meier method and compared using log-rank tests.
Results The median PFS period was 11.2 months. Ktrans, IAUC60, VEGF, and PlGF values on the first follow-up day were significantly different compared with baseline values. No differences were observed on the second follow-up day. A > 40% decrease in Ktrans from baseline to first follow-up was associated with a longer PFS (hazard ratio, 0.349; 95% confidence interval, 0.133 to 0.912; p=0.032). Changes in CAFs did not show correlation with PFS time. Conclusion DCE-MRI parameters and CAFs are pharmacodynamic biomarkers of bevacizumab for CRCLM. In our study, change in Ktrans at 3 days after bevacizumab monotherapy was a favorable prognostic factor; however, the value of CAFs as a prognostic biomarker was not found.
Citations
Citations to this article as recorded by
Decoding Tumor Angiogenesis for Therapeutic Advancements: Mechanistic Insights Geetika Kaur, Bipradas Roy Biomedicines.2024; 12(4): 827. CrossRef
Current trends in the characterization and monitoring of vascular response to cancer therapy Binita Shrestha, Noah B Stern, Annie Zhou, Andrew Dunn, Tyrone Porter Cancer Imaging.2024;[Epub] CrossRef
Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases Martina Caruso, Arnaldo Stanzione, Anna Prinster, Laura Micol Pizzuti, Arturo Brunetti, Simone Maurea, Pier Paolo Mainenti World Journal of Gastroenterology.2023; 29(3): 521. CrossRef
Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition Brandon M. Bordeau, Joseph Ryan Polli, Ferdinand Schweser, Hans Peter Grimm, Wolfgang F. Richter, Joseph P. Balthasar International Journal of Molecular Sciences.2022; 23(2): 679. CrossRef
The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids Sarah Line Bring Truelsen, Nabi Mousavi, Haoche Wei, Lucy Harvey, Rikke Stausholm, Erik Spillum, Grith Hagel, Klaus Qvortrup, Ole Thastrup, Henrik Harling, Harry Mellor, Jacob Thastrup, Christina L. Addison PLOS ONE.2021; 16(7): e0253258. CrossRef
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer Rohini Sharma, Pablo Oriol Valls, Marianna Inglese, Suraiya Dubash, Michelle Chen, Hani Gabra, Ana Montes, Amarnath Challapalli, Mubarik Arshad, George Tharakan, Ed Chambers, Tom Cole, Jingky P. Lozano-Kuehne, Tara D. Barwick, Eric O. Aboagye European Journal of Nuclear Medicine and Molecular Imaging.2020; 47(5): 1239. CrossRef
Combination of DCE‐MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma Changmin Liu, Roger Sun, Jing Wang, Fangling Ning, Zhenbo Wang, Judong Luo, Shaoshui Chen, Shuanghu Yuan, Enzo Terreno BioMed Research International.2020;[Epub] CrossRef
Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging Pier Paolo Mainenti, Arnaldo Stanzione, Salvatore Guarino, Valeria Romeo, Lorenzo Ugga, Federica Romano, Giovanni Storto, Simone Maurea, Arturo Brunetti World Journal of Gastroenterology.2019; 25(35): 5233. CrossRef
Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients Matteo Morotti, Prashanth Hari Dass, Adrian L. Harris, Simon Lord European Journal of Drug Metabolism and Pharmacokinetics.2018; 43(2): 137. CrossRef
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile BMC Cancer.2018;[Epub] CrossRef
Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases Pavitra Kannan, Warren W. Kretzschmar, Helen Winter, Daniel Warren, Russell Bates, Philip D. Allen, Nigar Syed, Benjamin Irving, Bartlomiej W. Papiez, Jakob Kaeppler, Bosjtan Markelc, Paul Kinchesh, Stuart Gilchrist, Sean Smart, Julia A. Schnabel, Tim Mau Clinical Cancer Research.2018; 24(19): 4694. CrossRef
Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy Marie Mogensen, Martin Hansen, Birthe Henriksen, Thomas Axelsen, Ben Vainer, Kell Osterlind, Michael Nielsen Diagnostics.2017; 7(2): 35. CrossRef
Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis Simonetta Geninatti Crich, Enzo Terreno, Silvio Aime Advanced Drug Delivery Reviews.2017; 119: 61. CrossRef